Trevi Therapeutics to Participate in Upcoming August Conferences
Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough related to idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough, announced its management's participation in key August biotech conferences to discuss clinical progress and company strategy.